Abstract:Objective To investigate the relation between altered expressions of EphA2 receptor tyrosine kinase and its ligand EphrinA1 and malignant phenotype of glioma cells, and explore the new targeting molecule for treating malignant gliomas. Methods The RNAi vector (plasmid pSilencer-EphA2-SR) against EphA2 was constructed and transfected into the malignant glioma cells (U251, U87 and SHG44). Forty-eight h after the transfection, the expressions of EphA2 and EphrinA1 were detected by Western blotting; the viability and anchorage independence of the glioma cells were observed by MTT assay and colony formation assay; the invasion viability and apoptosis of glioma cells were observed by modified Boyden chamber assay and flow cytometry. Glioma xenograft models were established in nude mice; plasmid pSilencer-EphA2-SR or pSilencer-null mixed with lipofectamine was intratumorally injected. The average tumor volume and weight of the transplanted gliomas were measured and compared; the expressions of EphA2 and EphrinA1 were detected by immunohistochemical staining.Results The RNAi plasmid against EphA2 was successfully constructed. After the transfection of plasmid pSilencer-EphA2-SR, the expression of endogenous EphA2 was suppressed, which consequently resulted in increased EphrinA1 level. As compared with cells of the plasmid pSilencer-null group, cells of the plasmid pSilencer-EphA2-SR group showed obviously decreased cell viability, anchorage independence rate and in vitro invasion ability, but significantly increased cell apoptosis rate (P＜0.05).Furthermore, suppression of EphA2 resulted in delayed tumor growth and increased EphrinA 1 expression in mice xenografts. Conclusion EphA2 and EphrinA1 may be key coupled-regulators for malignant phenotype of glioma cells. EphA2 suppression partially reverses the malignant phenotype of aggressive gliomas, possibly through up-regulating the EphrinA1 expression, which indicates that EphA2 and EphrinA1 might become the new targeting molecule for treatment of gliomas.

A review on the role of different ephrins in glioma

Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma

Function Study of Epha2 Gene in the Cell Apoptosis, Growth, Migration and Invasion of Glioma Cell Line U251

EphB4 is Overexpressed in Gliomas and Promotes the Growth of Glioma Cells

Expressions of EphA2 and EphrinA1 are associated with malignant phenotype of gliomas

EphB3 receptor suppressor invasion, migration and proliferation in glioma by inhibiting EGFR-PI3K/AKT signaling pathway

Altered expression of EphA2 and EphrinA1 is associated with prognosis of malignant glioma patients

Progress of erythropoietin-producing hepatocellular A2 receptor in glioma

Unveiling the therapeutic promise of EphA2 in glioblastoma: a comprehensive review

Pathological Significance of Epidermal Growth Factor Receptor Expression and Amplification in Human Gliomas

Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.

Eph Receptors: Actors in Tumor Microenvironment.

Expression of Ephrin-B2 Gene in Human Glioma and Its Implications

RNA Interference Targeting EphA2 Inhibits Proliferation, Induces Apoptosis, and Cooperates with Cytotoxic Drugs in Human Glioma Cells.

Ephs in cancer progression: complexity and context-dependent nature in signaling, angiogenesis and immunity

Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma

Significance of EphA2 Expression in Human Gliomas

EphA2, vascular endothelial growth factor, and vascular endothelial growth factor correlate with adverse outcomes and poor survival in patients with glioma

Eph receptors and ephrins as targets for cancer therapy.

EphA2-mediatedM1-like polarization of microglia attenuatesglioblastoma metastasis

Eph Receptors and Ephrins in Tumorigenesis